| Literature DB >> 35237532 |
Sergi Torres-Puig1, Vanesa García2,3, Kristian Stærk4, Thomas E Andersen4, Jakob Møller-Jensen1, John E Olsen2, Ana Herrero-Fresno2.
Abstract
Uropathogenic Escherichia coli (UPEC) is the main etiological agent of urinary tract infection (UTI), a widespread infectious disease of great impact on human health. This is further emphasized by the rapidly increase in antimicrobial resistance in UPEC, which compromises UTI treatment. UPEC biology is highly complex since uropathogens must adopt extracellular and intracellular lifestyles and adapt to different niches in the host. In this context, the implementation of forefront 'omics' technologies has provided substantial insight into the understanding of UPEC pathogenesis, which has opened the doors for new therapeutics and prophylactics discovery programs. Thus, 'omics' technologies applied to studies of UPEC during UTI, or in models of UTI, have revealed extensive lists of factors that are important for the ability of UPEC to cause disease. The multitude of large 'omics' datasets that have been generated calls for scrutinized analysis of specific factors that may be of interest for further development of novel treatment strategies. In this review, we describe main UPEC determinants involved in UTI as estimated by 'omics' studies, and we compare prediction of factors across the different 'omics' technologies, with a focus on those that have been confirmed to be relevant under UTI-related conditions. We also discuss current challenges and future perspectives regarding analysis of data to provide an overview and better understanding of UPEC mechanisms involved in pathogenesis which should assist in the selection of target sites for future prophylaxis and treatment.Entities:
Keywords: -omics; UPEC; UTIs; fitness; pathogenesis; virulence
Mesh:
Substances:
Year: 2022 PMID: 35237532 PMCID: PMC8882828 DOI: 10.3389/fcimb.2022.824039
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Figure 1Scheme of the workflow followed in this review. Selected articles based on ‘-omics’ technologies applied to UPEC were were scrutinized in order to identify fitness and virulence factors involved in UTIs. The identified factors were classified according to the stage of a UTI where they were involved in and validated targets were cross-referenced and tabulated. Created with BioRender.com.
Validated genes identified by TraDIS.
| Gene | Function (COG)5 | Validation study | UPEC strain | Reference | |||||
|---|---|---|---|---|---|---|---|---|---|
| Urine (bacteriuria) | Serum (urosepsis) | Infection of cells (cystitys) | Animal model(bladder, kidney) | Biofilm formation | Other | ||||
|
| F | X |
| ( | |||||
|
| – | X* | |||||||
|
| M,F |
| |||||||
|
| I | X | |||||||
|
| E,F | X | |||||||
|
| C,H | Murine bladder |
| ||||||
|
| M | Murine bladder | X | ||||||
|
| V,M | X* | LPS*/MI* | EC958 | ( | ||||
|
| R | X* | LPS*/MI* | ||||||
|
| O | X | LPS*/MI* | ||||||
|
| C | X | LPS*/MI* | ||||||
|
| – | X | LPS/MI* | ||||||
|
| – | X | LPS/MI* | ||||||
|
| K,G | X | LPS*/MI* | ||||||
|
| G | X | LPS/MI | ||||||
|
| G | X | LPS/MI | ||||||
|
| U | X | LPS*/MI | ||||||
|
| M | X | LPS*/MI | ||||||
|
| M | X | LPS/MI* | ||||||
|
| – | X | LPS/MI* | ||||||
|
| – | X | LPS*/MI* | ||||||
|
| M | X | LPS*/MI | ||||||
|
| M | X | LPS/MI* | ||||||
|
| G | X | LPS/MI | ||||||
|
| M | X | LPS/MI | ||||||
|
| M | X | LPS/MI* | ||||||
|
| M | X | LPS/MI* | ||||||
|
| M | X | LPS/MI* | ||||||
|
| M | X | LPS*/MI* | ||||||
|
| R | X | LPS/MI | ||||||
|
| M,G | X | LPS*/MI | ||||||
|
| M,G | X | LPS*/MI* | ||||||
|
| M,G | X | LPS*/MI* | ||||||
|
| M | X | LPS*/MI* | ||||||
|
| M | X | LPS*/MI | ||||||
|
| K | X | LPS*/MI | ||||||
|
| D | X | LPS*/MI | ||||||
|
| M |
| LPS/MI | ||||||
|
| M | X | LPS/MI | ||||||
|
| M | X | LPS/MI | ||||||
|
| M | X | LPS/MI | ||||||
|
| M | X | LPS/MI | ||||||
|
| M | X | LPS/MI* | ||||||
|
| M | X | LPS/MI | ||||||
|
| M | X | LPS/MI | ||||||
|
| F | X | LPS*/MI* | ||||||
|
| M | X | LPS/MI | ||||||
|
| M | X | LPS/MI | ||||||
|
| K | X | LPS/MI | ||||||
|
| E | X | LPS*/MI* | ||||||
|
| S | X* | LPS*/MI | ||||||
|
| C | X | LPS*/MI | ||||||
|
| K |
|
| ||||||
|
| O | X | LPS*/MI | ||||||
|
| G | X | LPS*/MI | ||||||
|
| J | X* | LPS*/MI | ||||||
|
| G | X | LPS*/MI* | ||||||
|
| C,P | X* | LPS*/MI* | ||||||
|
| U | X* | X7 | Bladder7/kidneys7 | LPS*/MI* | ||||
|
| G | X* | LPS*/MI* | ||||||
|
| J | X* | LPS*/MI* | ||||||
|
| K | X* | LPS*/MI* | ||||||
|
| M | X* | LPS*/MI* | ||||||
|
| N | Bladder/spleen/kidneys | CFT073 | ( | |||||
|
| N,W | Bladder/spleen/liver/kidneys | |||||||
|
| V | Spleen/liver | |||||||
|
| E | Spleen/liver | |||||||
|
| M | Spleen/liver | |||||||
|
| S | Spleen/liver | |||||||
|
| E | Spleen/liver | |||||||
|
| P | Spleen/liver | |||||||
|
| L | Spleen/liver | |||||||
|
| E | Bladder/spleen*/liver*/kidneys | |||||||
|
| T | Bladder/spleen*/liver*/kidneys | |||||||
|
| K | Hyper-motility | EC958 | ( | |||||
|
| L | Hyper-motility | |||||||
|
| T | Hyper-motility | |||||||
|
| K | Hyper-motility | |||||||
|
| K | Hyper-motility | |||||||
|
| J | Hyper-motility | |||||||
|
| J | Hyper-motility | |||||||
|
| – | Hyper-motility | |||||||
|
| K | Capsule synthesis | PA45B | ( | |||||
|
| K | Capsule synthesis | |||||||
|
| K | Capsule synthesis | |||||||
|
| T | Capsule synthesis | |||||||
|
| K | Capsule synthesis* | |||||||
|
| E | Capsule synthesis* | |||||||
|
| ? | Capsule synthesis* | |||||||
|
| M | Capsule synthesis* | |||||||
|
| ??? | Capsule synthesis* | |||||||
|
| S | Capsule synthesis* | |||||||
|
| G,P | Capsule synthesis* | |||||||
|
| C,P | Capsule synthesis* | |||||||
|
| – | Capsule synthesis* | |||||||
|
| M | Capsule synthesis* | |||||||
|
| J | Capsule synthesis* | |||||||
|
| E | Capsule synthesis* | |||||||
|
| I | Growth in mucus | UPEC F11 | ( | |||||
|
| G | Growth in mucus | |||||||
|
| S | Mouse gut | Growth in mucus | ||||||
|
| – | Growth in mucus* | |||||||
|
| H,R | Hemolysis | CFT073 | ( | |||||
|
| Q | Hemolysis | |||||||
|
| M | Colicin resistance | EC958 | ( | |||||
|
| O | Hemolysis (increased) | S65SC | ( | |||||
|
| H | Hemolysis | |||||||
|
| M | Hemolysis | |||||||
|
| M | Hemolysis | |||||||
|
| M | Hemolysis | |||||||
|
| O | Hemolysis | |||||||
|
| D | Human bladder cells, bladder and kidney (mice) | T1P expression, oxidative stress, hyper-motility | CFT073 | ( | ||||
|
| P | Zn resistance | EC958 | ( | |||||
|
| K,T | Zn resistance | |||||||
|
| K,T | Zn resistance | |||||||
|
| D | Zn resistance | |||||||
|
| O | Zn resistance | |||||||
|
| O | Zn resistance | |||||||
|
| D | Zn resistance | |||||||
|
| U | Zn resistance | |||||||
|
| P | Zn resistance | |||||||
|
| D | Zn resistance | |||||||
|
| D | Zn resistance | |||||||
|
| D | Zn resistance | |||||||
|
| M | Zn resistance | |||||||
|
| P | Zn resistance | |||||||
|
| I | Zn resistance* | |||||||
|
| U | Zn resistance* | |||||||
|
| T | Zn resistance | |||||||
|
| K | Zn resistance | |||||||
|
| C | Zn resistance | |||||||
|
| S | Zn resistance* | |||||||
|
| J | Zn resistance* | |||||||
|
| L | Zn resistance* | |||||||
|
| C | Zn resistance* | |||||||
|
| J | Zn resistance (tolerance) | |||||||
|
| P | Zn resistance (tolerance) | |||||||
|
| J | Zn resistance* | |||||||
|
| K | Zn resistance (tolerance) | |||||||
|
| L | Zn resistance* | |||||||
|
| T | Zn resistance (tolerance) | |||||||
|
| P | Zn resistance (tolerance) | |||||||
|
| D | Cefotaxime susceptibility* | EC958 | ( | |||||
|
| M | Cefotaxime susceptibility | |||||||
|
| U | Cefotaxime susceptibility | |||||||
|
| D | Cefotaxime susceptibility | |||||||
|
| V | Cefotaxime susceptibility | |||||||
|
| G,E,P,R | Cefotaxime susceptibility | |||||||
|
| M | Cefotaxime susceptibility | |||||||
|
| P | Cefotaxime susceptibility | |||||||
|
| D | Cefotaxime susceptibility | |||||||
|
| U | Cefotaxime susceptibility | |||||||
|
| L | Cefotaxime susceptibility | |||||||
|
| M | Cefotaxime susceptibility | |||||||
|
| D | Cefotaxime susceptibility | |||||||
|
| J | X | Bladder/kidneys | CFT073 | ( | ||||
|
| M | X | Bladder/kidneys* | ||||||
|
| E,F |
| Bladder/kidneys* | ||||||
|
| N | X | Bladder/kidneys* | ||||||
|
| T | X | Bladder/kidneys* | ||||||
|
| T | X | Bladder/kidneys* | ||||||
|
| F | X | Bladder/kidneys | ||||||
|
| V,M | X | Bladder*/kidneys* | ||||||
|
| M,G | X* | Bladder*/kidneys* | ||||||
|
| P | X* | Bladder*/kidneys* | ||||||
|
| U | X* | Bladder*/kidneys* | ||||||
|
| S | X* | Bladder*/kidneys* | ||||||
|
| H | Human* | |||||||
|
| H | Human | |||||||
|
| J | Human* | |||||||
|
| I | Human* | |||||||
|
| J | Human* | |||||||
|
| H | Human | |||||||
|
| M | Human* | |||||||
|
| J | Human | |||||||
|
| C,P | Human* | UTI89 | ( | |||||
|
| J | Human | |||||||
|
| U | Human* | |||||||
|
| U | Human* | |||||||
|
| M | Human* | |||||||
|
| S | Human* | |||||||
|
| O | Human* | |||||||
|
| J | Human | |||||||
|
| G | Human | |||||||
|
| M | Human | |||||||
|
| M | Human | Bladder | ||||||
|
| K,T | Human | |||||||
|
| L | Human | |||||||
|
| J,O,H | Human | |||||||
|
| C | Human* | |||||||
|
| C | Human* | Bladder | ||||||
|
| M | Human* | Bladder | ||||||
|
| P | Human* | Bladder | ||||||
|
| K | Human | |||||||
|
| D | Bladder | |||||||
|
| G,E | Bladder | |||||||
|
| L | Bladder | |||||||
|
| P | Bladder | |||||||
|
| K | Bladder | |||||||
|
| M | Bladder | |||||||
|
| O | Bladder* | |||||||
1Genes could not be validated because of high fitness defects of the single individual mutant strain.
2Gene was overexpressed due to a transposon insertion at the promoter region.
3Gene also validated in PA45 and UTI89 UPEC strains.
4O-antigen gene identified by Sharp et al. (2019) was not directly validated in ST131 EC958; instead, O-antigen density induction in strain MG1655 was used as a comparison (strains L5 and L9).
5Cluster of Orthologous Groups (COG) Code: C, Energy production and conversion; D, Cell cycle control, cell division, chromosome partitioning; E, Amino Acid metabolism and transport; F, Nucleotide metabolism and transport; G, Carbohydrate metabolism and transport; H, Coenzyme metabolism and transport; I, Lipid metabolism and transport; J, Translation, ribosomal structure and biogenesis; K, Transcription; L, Replication, recombination and repair; M, Cell wall/membrane/envelop biogenesis; N, Cell motility; O, Post-translational modification, protein turnover, chaperone functions; P, Inorganic ion transport and metabolism; Q, Secondary metabolites biosynthesis, transport and catabolism; R, General function prediction only; S, Function unknown; T, Signal Transduction; U, Intracellular trafficking, secretion and vesicular transport; V, Defense mechanisms; W, extracellular structures.
6Genes described in this study were identified using a Multiple round PCR approach.
7Functions were assayed in CFT073 by Hirakawa et al. (2019).
*Functions were assayed but could not be confirmed in single specific mutants.
In bold is indicated genes and functions that have been also assayed in single mutants in several studies other than in the TIS study in which the gene was identified. UPEC strain used, and the reference are also highlighted in bold. LPS: Altered LPS patterns compared to WT.
Validated genes identified by transcriptomics.
| Gene | Function (COG)2 | Validation study | UPEC strain | Reference | |||||
|---|---|---|---|---|---|---|---|---|---|
| Urine (bacteriuria) | Serum (urosepsis) | Infection of cells (cystitys) | Animal model(bladder, kidney) | Biofilm formation | Other | ||||
|
| S | Human urine | 83972 | ( | |||||
|
| S | Human urine | |||||||
|
| S | Human urine | |||||||
|
| S | Human urine | |||||||
|
| K | Bladder*, kidney | Increased motility | CFT073 | ( | ||||
|
| S | X | Reduced motility on agar | CFT073 | ( | ||||
|
| S | X | Reduced motility on agar | ||||||
|
| S | X* | |||||||
|
| T | X | X | IBC formation, motility | UTI89 | ( | |||
|
| C | X | IBC formation, motility | ||||||
|
| C | X | IBC formation, motility | ||||||
|
| C | X | IBC formation, motility | ||||||
|
| G,K | Mouse | Bladder, kidney | CFT073 | ( | ||||
|
| K | Mouse | Bladder*, kidney | X | Motility | ||||
|
| M | X | CFT073 | ( | |||||
|
| K | X | |||||||
|
| K | X | |||||||
|
| K | X | |||||||
|
| S | X | |||||||
|
| X* | ||||||||
|
| S | X* | |||||||
|
| K | X* | |||||||
|
| T | X* | |||||||
|
| X | CFT073 | ( | ||||||
|
| K | X | |||||||
|
| C | X | |||||||
|
| P | X | |||||||
|
| P | X | |||||||
|
| – | X* | |||||||
|
| P | X* | |||||||
|
| M | X* | |||||||
|
| K | X* | |||||||
|
| K,T | Survival mouse bone marrow-derived macrophages | UTI89 | ( | |||||
|
| M | IBC formation | UTI89 | ( | |||||
|
| Q | IBC formation* | |||||||
|
| Q | IBC formation* | |||||||
|
| P | IBC formation* | |||||||
|
| P | IBC formation* | |||||||
|
| P | Bladder, kidney, spleen | Growth | 536 | ( | ||||
|
| U | X | UTI89 | ( | |||||
|
| G | X | |||||||
|
| P | X | X | Type 1 piliation, tellurite and oxidate stress sensitivity | |||||
|
| G | X | |||||||
|
| F | X | |||||||
|
| Q | ||||||||
|
| – | X | X | CFT073 | ( | ||||
1This gene was initially detected in a transcriptomics assay and further validated by Dbeibo et al., 2018, in an animal model (bladder and kidneys).
2COG Code: C, Energy production and conversion; F, Nucleotide metabolism and transport; G, Carbohydrate metabolism and transport; K, Transcription; M, Cell wall/membrane/envelop biogenesis; N, Cell motility; P, Inorganic ion transport and metabolism; Q, Secondary metabolites biosynthesis, transport, and catabolism; S, Function unknown; T, Signal Transduction; U, Intracellular trafficking, secretion and vesicular transport.
IBC, Intracellular bacterial communities.
*Genes tested in validation assays whose role could not be confirmed under the tested conditions.
#Deletion of the gene was unsuccessful despite several attempts.
Validated genes identified by proteomics.
| Gene | Function (COG)2 | Validation study | UPEC strain | Reference | |||||
|---|---|---|---|---|---|---|---|---|---|
| Urine (bacteriuria) | Serum (urosepsis) | Infection of cells (cystitys) | Animal model(bladder, kidney) | Biofilm formation | Other | ||||
|
| E | X | CFT073 | ( | |||||
|
| E | X | |||||||
|
| F | X | |||||||
|
| E | X | |||||||
|
| C | X | |||||||
|
| F | X | |||||||
|
| F | X* | |||||||
|
| G | X* | |||||||
|
| E | X* | |||||||
|
| G | X* | |||||||
|
| H | X* | |||||||
|
| F | X* | |||||||
|
| G | X* | |||||||
|
| E,G | X* | |||||||
|
| F | X* | |||||||
|
| F | X* | |||||||
|
| – | X | X | Fimbrial production cell surface | 536 | ( | |||
|
| M | X* | CFT073 | ( | |||||
|
| E | X* | CFT073 | ( | |||||
|
| F | X | CFT073 | ( | |||||
|
| C | X* | CFT073 | ( | |||||
|
| P | X* | CFT073 | ( | |||||
|
| M | X | CFT073 | ( | |||||
|
| M | X* | CFT073 | ( | |||||
|
| M | X* | CFT073 | ( | |||||
|
| M | X* | CFT073 | ( | |||||
|
| F | X | CFT073 | ( | |||||
|
| U | X* | CFT073 | ( | |||||
|
| S | X | CFT073 | ( | |||||
|
| L | X | CFT073 | ( | |||||
1Genes detected by proteomics but validated in other studies using similar conditions. In bold is indicated the UPEC strain used for the validation assays when it differs from the UPEC strain employed in the proteomics analysis.
2COG Code: C, Energy production and conversion; E, Amino Acid metabolism and transport; F, Nucleotide metabolism and transport; G, Carbohydrate metabolism and transport; H, Coenzyme metabolism and transport; L, Replication, recombination and repair; M, Cell wall/membrane/envelop biogenesis; P, Inorganic ion transport and metabolism; S, Function unknown; U, Intracellular trafficking, secretion and vesicular transport.
*Genes tested in validation assays whose role could not be confirmed under the tested conditions.
Validated genes identified by more than one -omics approach during any of the UTI stages.
| Gene | Function (COG)1 | ‘Omics’ approach2 | Reference |
|---|---|---|---|
|
| F | TN, TR, P | ( |
|
| O | TR, P | ( |
|
| E | TN, P | ( |
|
| F | TN, P | ( |
|
| F | TN, P | ( |
|
| C | TN, TR, P | ( |
|
| C | TN, TR | ( |
|
| F | TN, P | ( |
|
| M | TR, P | ( |
|
| C | TR, P | ( |
|
| D | TN, P | ( |
|
| F | TR, P | ( |
|
| O | TR, TN | ( |
|
| J | TN, TR | ( |
|
| F | TR, P | ( |
|
| M | TN, P | ( |
|
| N | TN, P | ( |
|
| J | TN, TR, P | ( |
|
| F | TR, P | ( |
|
| D | TN, TR | ( |
|
| F | TN, TR | ( |
|
| F | TN, TR | ( |
|
| F | TN, TR | ( |
|
| C, G | TR, P | ( |
|
| P | TR, P | ( |
|
| C, E | TN, P | ( |
|
| C | TR, P | ( |
|
| M | TN, P | ( |
|
| E | TN, TR | ( |
|
| K | TN, TR | ( |
|
| P | TN, TR | ( |
|
| TN, P | ( | |
|
| M | TN, TR, P | ( |
|
| E | TN, P | ( |
|
| K | TN, TR | ( |
|
| P | TR, P | ( |
|
| F | TN, P | ( |
|
| M | TN, TR | ( |
|
| J | TR, P | ( |
|
| J | TR, P | ( |
|
| K | TR, P | ( |
|
| K | TN, TR | ( |
|
| J | TN, P | ( |
|
| M | TN, P | ( |
|
| K | TN, P | ( |
|
| O | TN, P | ( |
|
| M | TN, P | ( |
|
| F | TR, P | ( |
|
| J | TR, P | ( |
|
| G | TR, P | ( |
|
| G | TR, P | ( |
|
| S | TN, TR | ( |
|
| S | TN, TR | ( |
|
| D | TN, TR | ( |
|
| M | TR, P | ( |
|
| S | TR, P | ( |
|
| S | TN, P | ( |
|
| TN, TR | ( | |
|
| S | TR, P | ( |
1COG Code: C, Energy production and conversion; D, Cell cycle control, cell division, chromosome partitioning; E, Amino Acid metabolism and transport; F, Nucleotide metabolism and transport; G, Carbohydrate metabolism and transport; J, Translation, ribosomal structure and biogenesis; K, Transcription; M, Cell wall/membrane/envelop biogenesis; N, Cell motility; O, Post-translational modification, protein turnover, chaperone functions; P, Inorganic ion transport and metabolism; S, Function unknown.
2P, proteomics; TN, TraDIS; TR, transcriptomics.